Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Detection of endometrial cancer

A technology for endometrial cancer and endometrium, which is applied in the field of endometrial cancer detection and can solve problems such as undetected

Inactive Publication Date: 2000-06-21
默尔本大学 +1
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] We have now unexpectedly found that matrix metalloproteinases can be detected in uterine washings from patients with endometrial cancer but not from control women

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Detection of endometrial cancer
  • Detection of endometrial cancer
  • Detection of endometrial cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0077] Example 1 Release of MMPs into the Uterine Cavity of Patients Undergoing Endometrial Cancer Study

[0078] Samples from 52 endometrial cancer patients and 40 control patients undergoing diagnostic procedures for uterine bleeding or other gynecological diseases were examined for MMP-2 and MMP-9 by zymography and by image cytometry DNA ploidy of endometrial surface cells. Patients found to have endometrial cancer were assessed for grade of malignancy. MMP-2 and MMP-9 were further divided into the following hypothetical assay types: latent MMP-2, active MMP-2, dimeric MMP-9, preglycosylated MMP-9 and activated MMP-9. The identification of latent and active MMP-2 and MMP-9 was subsequently determined as described in the Examples below.

[0079] The results are summarized in Tables 1 and 2. In addition, MMP-1, MMP-3, and MMP-7 were measured by casein zymography, but no detectable levels were found in either controls or uterine washings from patients with endometrial cance...

Embodiment 2

[0098] Example 2 ELISA analysis of MMP-9 and MMP-2

[0099] Biotrak TM MMP-9 ELISA Kit (Calbiochem R), capable of providing simple and specific detection of MMP-9 in uterine wash samples. The assay has a sensitivity of 0.6 ng / ml. This assay uses two antibodies directed against different epitopes of MMP-9. All MMP-9 present in the samples or standards was bound to microtiter plates previously coated with anti-MMP-9. This is followed by a second incubation step in which a detection antibody conjugated to horseradish peroxidase is added to form an immobilized complex. Tetramethylbenzidine substrate was added to each well, and a color reaction was performed to detect the amount of peroxidase complex in each well. The blue color of the product was measured at 630 nm using a microtiter plate spectrophotometer (Beckman). Prepare a standard curve by plotting the average optical density at 630 nm against the standard ng / ml. The concentration (ng / ml) of each sample was determine...

Embodiment 3

[0102] Example 3 Cell Biology Research

[0103] Hysterectomy is part of the treatment for patients who have been diagnosed with uterine cancer. After hysterectomy, endometrial tissue is removed, if possible, from the following two locations:

[0104] (a) corresponding to the location of the malignant lesion,

[0105] (b) On microscopic examination, the endometrium appears to be in a normal position.

[0106] Both tumor tissue and normal tissue were in the presence of 0.15M NaCl, 10mM CaCl 2 , and 0.05% Brij35 in 50 mM Tris-HCl buffer (pH 7.5), and homogenate on ice. The supernatant was obtained by centrifugation, and the protein concentration was determined by the dye binding method with BilRad protein assay reagent.

[0107] Examination of MMP phenotypes in tissue homogenates by gelatin zymography. Supernatants, calibrated to have the same amount of protein in each lane, were poured into gels with gelatin and subjected to SDS-PAGE as above.

[0108] Zymograms showed rel...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to View More

Abstract

This invention relates to methods for assaying the presence and / or risk of endometrial cancer by measurement of levels of matrix metalloproteinase-2 and / or matrix metalloproteinase-9 in uterine washings. The method may be qualitative or quantitative, and is adaptable to large-scale screening and to clinical trials.

Description

[0001] The invention relates to a detection method for cancer, especially a detection method for endometrial cancer. The methods of the invention are suitable for large-scale screening, eg, in women at increased risk of endometrial cancer. Background of the invention [0002] It is now well known that in some malignant tumors, there is a high correlation between tumor invasiveness and tumor cell protease expression. For example, during the last seven years, convincing evidence has accumulated that the process of tumor invasion and metastasis is directly related to members of the matrix metalloproteinase family. [0003] Clinicians have long recognized the need to develop objective criteria for the early detection of cancer and for evaluating prognostic factors when treating patients with malignancies. Generally, judging the stage of endometrial cancer, the depth of invasion into the myometrium, the histological grade and type of the tumor, and the degree of invasion into the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/37G01N33/574
CPCG01N33/57442G01N2333/96494C12Q1/37
Inventor 亚历山大·罗帕塔洛伊丝·A·萨拉蒙森迈克尔·A·奎因
Owner 默尔本大学
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products